Sanofi's M&A plans of insulin company hit by FTC delayApril 11, 2023 - Sanofi had to withdraw and refile its proposal to acquire Provention Bio to give the Federal Trade Commission more time to complete its review. The centerpiece of the deal, Tzield, is the first and only FDA-approved treatment to delay the onset of Type 1 diabetes. The acquisition builds on a previous co-promotion pact, under which Sanofi lended its commercialization clout.
https://www.fiercepharma.com/pharma/sanofis-29b-deal-provention-bio-hit-protracted-ftc-review-wheres-pfizer-seagen